FendX and Aquaox Sign MOU to Pursue Innovation in Sustainable Pathogen Elimination
Rhea-AI Summary
FendX (OTCQB: FDXTF) signed a Memorandum of Understanding dated November 17, 2025 with Aquaox to pursue development of advanced formulations of eco‑friendly pathogen‑eliminating agents for use in cleaning and disinfectant products across healthcare, consumer, and commercial markets.
The MOU contemplates a collaboration and supply relationship under a future Definitive Agreement, states Aquaox will oversee production equipment and supply, and says FendX will own any products and new intellectual property while Aquaox will own any new EPA certifications. The MOU term is 12 months and the Definitive Agreement is subject to due diligence and regulatory and corporate approvals, with no assurance it will be completed.
Positive
- MOU executed on November 17, 2025
- MOU term of 12 months
- FendX to own any new products and new intellectual property
- Aquaox to provide production equipment and supply responsibility
Negative
- Definitive Agreement is conditional on due diligence and approvals
- There is no assurance the Definitive Agreement will be entered
- Aquaox will own any new EPA certifications, not FendX
News Market Reaction – FDXTF
On the day this news was published, FDXTF gained 24.67%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Strategic partnership to develop advanced formulations of eco-friendly pathogen-elimination agents and expand FendX's hygiene solutions portfolio
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has signed a Memorandum of Understanding ("MOU") dated November 17, 2025 with Aquaox LLC ("Aquaox"), a U.S. based manufacturer of environmentally responsible disinfectants.
Under the MOU, FendX and Aquaox intend to negotiate and enter into a collaboration and supply agreement (the "Definitive Agreement") with the objective of developing advanced formulations of eco-friendly pathogen-eliminating agents. FendX plans to use these agents in new cleaning and disinfectant products for healthcare, consumer and commercial markets.
"This collaboration is an important step forward for FendX," said Dr. Carolyn Myers, CEO of FendX. "Expansion into the disinfectant and cleaning market will complement our existing surface protection technologies and support our goal of reducing pathogen transmission. Working with Aquaox enables us to combine their expertise in disinfection, formulation and manufacturing with our product development capabilities to deliver practical, effective hygiene solutions that will strengthen our portfolio and provide a meaningful alternative to existing products."
"Partnering with FendX aligns well with our mission and proven track record in sustainable disinfection," said Michel van Schaik, CEO of Aquaox. "Our success in developing hypochlorous acid-based technologies and building strong commercial partnerships has led to our revenue growth. We see this MOU as an opportunity to extend that momentum by partnering with FendX to pioneer innovative, green technologies that advance how we protect health and hygiene."
Under the Definitive Agreement, FendX and Aquaox will collaborate to develop advanced formulations of eco-friendly pathogen-eliminating agents. Aquaox will oversee the development and maintenance of the equipment required to produce and supply these agents to FendX who will use them to develop cleaning and disinfectant products of its choosing. Any products developed by FendX, along with any new intellectual property, will be owned by FendX. Aquaox will own of all new EPA certifications granted for the agents and provide FendX access to these certifications.
Entering into the Definitive Agreement is subject to certain conditions, including but not limited to, final due diligence by the parties, receipt of applicable corporate and regulatory approvals by the Company, including that of the CSE, if applicable. There can be no assurance that the Definitive Agreement will be entered into as proposed herein or at all. The MOU has a term of 12 months unless extended, is terminated with 30 day's written notice or superseded by the Definitive Agreement.
About FendX Technologies Inc.
FendX is a surface protection company developing innovative solutions to help reduce the spread of harmful pathogens in everyday environments. Leveraging proprietary technologies, The Company is advancing a portfolio of protective surface coatings, including REPELWRAP™ film, a liquid-based nano-coating technology and a specialized Foley catheter coating. The Company is focussed on building a robust intellectual property portfolio in the surface protection space and is committed to identifying and advancing new technologies and materials that enhance hygiene and safety across healthcare, consumer and commercial settings. Learn more at: https://fendxtech.com.
About Aquaox LLC.
Aquaox LLC is a U.S.-based manufacturer of environmentally responsible disinfectants, specializing in hypochlorous acid ("HOCl") technologies. The company has successfully commercialized its HOCl-based compounds through strategic partnerships, contributing to their revenue growth across healthcare, commercial, and industrial sectors. Aquaox is committed to delivering safe, sustainable alternatives to conventional chemical disinfectants.
ON BEHALF OF THE COMPANY
"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director
For further information, please contact:
Investor Relations
Phone: 1-800-344-9868
Email: investor@fendxtech.com
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; the entry into the proposed Definitive Agreement and proposed terms and collaboration plans; statements regarding the development of advanced formulations of eco-friendly pathogen-eliminating agents with Aquaox; statements regarding the development and commercialization of new pathogen-control products/hygiene solutions by FendX, including their benefits and proposed target markets including healthcare, consumer and commercial markets; statements regarding expansion into the disinfectant and cleaning market; statements regarding expanding the Company's product and IP portfolio; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the Definitive Agreement will not be finalized; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including development initiatives resulting from the Definitive Agreement; risks related to research and development activities for each of the film, spray formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives; risks that the Company may not expand its product pipeline or execute its business development and growth plans, including not being able to develop any new agents or products nor develop any new intellectual property as a result of its collaboration with Aquaox; risks that the Company's products, including any new products that may be developed, may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its IP; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at www.sedarplus.ca.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274856
FAQ
What did FendX (FDXTF) announce on November 18, 2025?
What is the length and termination term of the FendX–Aquaox MOU?
Who will own products and IP developed under the proposed FendX agreement?
Will FendX automatically receive EPA certifications for the agents developed with Aquaox?
Is the FendX–Aquaox collaboration finalized and binding for shareholders?
What role will Aquaox play in supplying FendX under the proposed deal?
